Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
about
The kallikrein-kinin system in diabetic nephropathyElectrical vagus nerve stimulation for the treatment of chronic heart failureEffects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failureLong-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertensionLosartan prevents heart fibrosis induced by long-term intensive exercise in an animal modelRamipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrusMurine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotesInteraction between AT1 and AT2 receptors during postinfarction left ventricular remodeling.Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling.Direct stimulation of angiotensin II type 2 receptor enhances spatial memoryNew competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression.Silent disease progression in clinically stable heart failure.Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarctionSilent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease.Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma.Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides.Disease-dependent mechanisms of albuminuria.Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cellsExercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats.Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction.Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trialsLocal angiotensin II aggravates cardiac remodeling in hypertension.Therapeutic potential of angiotensin II receptor antagonists.Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure.Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptorsEffects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.Angiotensin AT2 receptors: cardiovascular hope or hype?AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR.The role of angiotensin II receptor blockers in the treatment of heart failure patients.Angiotensin II receptor blockers in heart failure.Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarctionTargeting signaling pathways in heart failure by gene transfer.The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction.Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension
P2860
Q26827473-5BCB5261-C0C5-4837-A826-8E34CA8CFFE4Q26851442-6B56A059-C8CD-49F1-987B-4F3C454D71C0Q28346745-35DF2F53-C47E-49C4-BAD7-A374E0BDE520Q28367770-27DA4402-F990-43A5-80BB-94B133887DE9Q28485917-EFC0F21C-EEF3-4583-9E96-C68568570813Q28580234-BDCA7825-DFAA-4ED9-994B-CB2BC282D858Q28592947-AEF2A9DC-6AFC-4B0F-AC6E-36CC2BB0068FQ30438294-2EAAD302-CE32-4F95-8D2F-4C16509A3CA1Q30444722-AF7A3369-E880-441A-8F98-B00602DC576BQ30504733-5AEF7375-1890-4DB5-9AEE-C3BEECECE973Q31989723-F52D6BE8-C9A3-4F0B-B773-4B042A1E0F53Q33428533-AA2A3059-90FF-4BE9-B3E2-FA1A6348AE31Q33578212-79F7D1D9-3588-4072-87AA-097CB9BB7408Q33623829-46C642BF-F808-4E11-882A-C5558D4173FEQ33650781-71A99401-15FE-49E0-BE4C-BFDF90F0A223Q33760484-88F9C288-6ACA-48D2-9960-93DE87A2EAA1Q33896918-CB1F29DB-5C33-4A92-896F-F496509E08DDQ33928318-8AFC8183-FA3C-445F-9E2A-4B63FFE119DCQ34012444-1E0D9B38-5FC8-41AF-B4D4-8697E4FA29A0Q34051055-BD59EBD1-89F6-47A9-A885-0619C6D1DA21Q34075614-CE9508A8-ADE1-481D-8728-A26D6D758852Q34137730-0FF781A8-21EB-4C09-A932-FEFCA29C8FBBQ34296720-3C8FE42C-1540-47B6-B013-129281029A47Q34325432-6F38DF1C-BF91-4404-98A4-F57902C0B2E8Q34357832-F193F493-7601-49F3-9E35-9A7DD98F8F43Q34481715-652FC871-3E3C-4D46-87A7-A9BD5761B333Q34482530-131512AA-8B33-47FD-AC6D-1252BBBE7347Q34625492-C59BA6F2-A4AE-47CE-ACC9-5CC7E2EB3BE8Q35025287-092BBD12-9023-4C8A-B539-7C678B403FF7Q35044907-787FFDBE-EF6E-493E-90A9-733BEC958597Q35045801-4EDDB287-44EA-4C02-BFA4-013731476242Q35047332-756A91DD-AB57-4499-9589-11AA03BCD1FFQ35056228-4F5200CC-C1FD-40FC-84CE-686ED3CE8691Q35066800-8586031A-76B3-4E31-A2BD-ABBA60041D1FQ35070256-E941E744-94CB-438B-B245-C74E311C1E51Q35095401-23570A3F-F5E1-4F10-9AD7-B4E3AF92EC32Q35148421-063D0EA2-1ED6-4A4C-A709-F7701E97C783Q35406226-A65ED21A-8CE6-408E-AD2C-D45F695070A1Q35642421-50D0B0DD-9F88-41EF-BBD7-F01827AEFA40Q35670580-D79AC88F-9BAB-46AD-89B4-65D7B0391F8E
P2860
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@en
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@nl
type
label
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@en
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@nl
prefLabel
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@en
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@nl
P2093
P2860
P356
P1476
Effects of angiotensin-convert ...... giotensin II type 2 receptors.
@en
P2093
E Peterson
H N Sabbah
O A Carretero
V G Sharov
P2860
P304
P356
10.1172/JCI119360
P407
P577
1997-04-01T00:00:00Z